Blog
RSS FeedPosted by Michael Wonder on 10 Jun 2020
Final NHS green light for Roche's Kadcyla
10 June 2020 - NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant ...
Posted by Michael Wonder on 08 Jun 2020
NICE publishes appraisal consultation for isatuximab in combination with pomalidomide and dexamethasone for treating patients with relapsed and refractory multiple myeloma
4 June 2020 - The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees ...
Posted by Michael Wonder on 27 May 2020
NICE issues final guidance on NHS use of Bayer's Vitrakvi
27 May 2020 - The NICE has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety ...
Posted by Michael Wonder on 27 May 2020
NICE recommends treatment for type of small-cell lung cancer
27 May 2020 - A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE. ...
Posted by Michael Wonder on 22 May 2020
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
22 May 2020 - Draft guidance published today by NICE recommends atezolizumab for treating people with a type of breast cancer, ...
Posted by Michael Wonder on 13 May 2020
NICE backs drug for lymphoma from Roche
13 May 2020 - NICE has recommended NHS funding for a cancer drug, giving final guidance on a new option ...
Posted by Michael Wonder on 13 May 2020
NICE final guidance backs Pfizer's Lorviqua
13 May 2020 - NICE has published guidance recommending the use of Pfizer's Lorviqua (lorlatinib) for a certain form of ...
Posted by Michael Wonder on 07 May 2020
NICE draft guidance recommends new treatment option for people with early breast cancer
7 May 2020 - NICE has today published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) ...
Posted by Michael Wonder on 16 Mar 2020
NICE hits Keytruda with ‘no’ for urothelial cancer
12 March 2020 - NICE has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) ...
Posted by Michael Wonder on 27 Feb 2020
NICE recommends new ‘chemotherapy-free’ treatment for lymphoma
27 February 2020 - A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been ...
Posted by Michael Wonder on 26 Feb 2020
Polivy struck by NICE ‘no’
26 February 2020 - The National Institute for Health and Care Excellence has announced that it does not recommend Polivy ...
Posted by Michael Wonder on 12 Feb 2020
NICE refuses Keytruda, Inlyta cancer combo
12 February 2020 - NICE has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used in combo with Pfizer’s ...
Posted by Michael Wonder on 29 Jan 2020
Cancer patients facing delays in getting ‘innovative’ drugs
29 January 2020 - A new analysis report has found that most innovative cancer drugs face delays in reaching patients. ...
Posted by Michael Wonder on 23 Jan 2020
Woman denied cancer drug on NHS which could extend her life because of where she lives
22 January 2020 - Ann, 64, can't get the drug she needs to survive because it's not available on the NHS ...
Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...